Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.67 |
| ▸ | RARB | P10826 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.60 |
| ▸ | STS | P08842 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223346 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL5222917 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL5219396 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL10808590 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL5219438 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL14672532 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL11126885 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL9636880 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL5215164 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 | |
| SCHEMBL5220083 | 1.00 | TP53 (0.69) | TP53TSHRPLA2G4BRARBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472215-A4 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-05-09 | — | — | EP | disclosed |
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1472215-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0497297-B1 | Liquid crystal compound and liquid crystal display device | MITSUBISHI GAS CHEMICAL CO (JP) | 1998-04-08 | — | — | EP | disclosed |
| US-5364560-A | Liquid crystal compound and liquid crystal display device | MITSUBISHI GAS CHEMICAL CO., INC. (JP) | 1994-11-15 | — | — | US | disclosed |
| EP-0497297-A2 | Liquid crystal compound and liquid crystal display device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-4251545-A | Fungicidal process using 1-(alkoxyaroyl)guanidines | GAF CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | TP53 4867/4885TSHR 1990/4885PLA2G4B 660/4885 |
| US-20050131032-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | TP53 4867/4885TSHR 1990/4885PLA2G4B 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.